Craig C. Hofmeister
Experienced in Hypophosphatemia

Dr. Craig C. Hofmeister

Hematology Oncology
Emory health
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
27 Years of Experience
Experienced in Hypophosphatemia
Emory health
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Craig Hofmeister is a Hematologist Oncology provider in Atlanta, Georgia. Dr. Hofmeister has been practicing medicine for over 27 years and is rated as an Experienced provider by MediFind in the treatment of Hypophosphatemia. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 135 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hypophosphatemia.

Graduate Institution
Ohio State University College Of Medicine, 1999.0
Residency
Loyola Univ. Medical Center
Specialties
Hematology Oncology
Licenses
Internal Medicine in GA
Board Certifications
American Board Of Internal Medicine, 2005
Fellowships
Loyola Univ. Medical Center
Hospital Affiliations
Grady Memorial Hospital
Emory University Hospital Midtown
Emory University Hospital
Saint Joseph's Hospital Of Atlanta, Inc
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, Atlanta, GA 30322
Call: 404-778-0519

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Phase 1 of Exposure Targeted Melphalan Dosing
Phase 1 of Exposure Targeted Melphalan Dosing
Enrollment Status: Recruiting
Publish Date: May 31, 2025
Intervention Type: Procedure, Drug, Other
Study Drug: Melphalan
Study Phase: Phase 1
Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis
Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis
Enrollment Status: Recruiting
Publish Date: January 29, 2025
Intervention Type: Procedure
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drug: KPT-8602
Study Phase: Phase 1/Phase 2
Slow-Go Strategy for High Risk AL Amyloidosis: Isatuximab for Upfront Therapy
Slow-Go Strategy for High Risk AL Amyloidosis: Isatuximab for Upfront Therapy
Enrollment Status: Active_not_recruiting
Publish Date: February 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Bortezomib, Cyclophosphamide, Dexamethasone, Isatuximab
Study Phase: Phase 1
Phase 1 / 2 Trial of Idasanutlin in Combination With Ixazomib and Dexamethasone in Patients With 17p Deleted, Relapsed Multiple Myeloma
Phase 1 / 2 Trial of Idasanutlin in Combination With Ixazomib and Dexamethasone in Patients With 17p Deleted, Relapsed Multiple Myeloma
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drugs: Dexamethasone, Idasanutlin, Ixazomib Citrate
Study Phase: Phase 1/Phase 2
Pilot Trial Evaluating Viral Protein Production From the Combination of Reolysin and Carfilzomib in Multiple Myeloma
Pilot Trial Evaluating Viral Protein Production From the Combination of Reolysin and Carfilzomib in Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Biological, Other, Drug
Study Drugs: Carfilzomib, Dexamethasone, Pelareorep
Study Phase: Phase 1
PD1 Blockade and Oncolytic Virus in Relapsed Multiple Myeloma
PD1 Blockade and Oncolytic Virus in Relapsed Multiple Myeloma
Enrollment Status: Completed
Publish Date: October 06, 2023
Intervention Type: Biological, Drug
Study Drugs: Carfilzomib, Dexamethasone, Nivolumab, Pelareorep
Study Phase: Phase 1
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
Enrollment Status: Unknown
Publish Date: February 16, 2023
Intervention Type: Biological
Study Drug: CYNK-001
Study Phase: Phase 1
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: February 04, 2021
Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Multiple Myeloma
Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 18, 2020
Intervention Type: Drug
Study Phase: Phase 1
Randomized Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant
Randomized Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant
Enrollment Status: Withdrawn
Publish Date: February 21, 2020
Intervention Type: Drug, Other
Study Phase: Phase 2
Daratumumab Infusion Acceleration
Daratumumab Infusion Acceleration
Enrollment Status: Completed
Publish Date: September 09, 2019
Intervention Type: Biological
Study Phase: Phase 2
Phase I Study of AR-42 in Relapsed Myeloma, Chronic Lymphocytic Leukemia, and Lymphoma
Phase I Study of AR-42 in Relapsed Myeloma, Chronic Lymphocytic Leukemia, and Lymphoma
Enrollment Status: Completed
Publish Date: June 04, 2018
Intervention Type: Other, Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

135 Total Publications

Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy.
Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy.
Journal: The Journal of clinical investigation
Published: August 05, 2025
View All 135 Publications
Similar Doctors
Experienced in Hypophosphatemia
Dr. Shruti C. Gupta
Hematology Oncology
Experienced in Hypophosphatemia
Dr. Shruti C. Gupta
Hematology Oncology
49 Jesse Hill Jr Dr Se, 
Atlanta, GA 
 (0.1 miles away)
404-778-7777
Languages Spoken:
English
See accepted insurances

Shruti Gupta is a Hematologist Oncology provider in Atlanta, Georgia. Dr. Gupta is rated as an Advanced provider by MediFind in the treatment of Hypophosphatemia. Her top areas of expertise are Interstitial Nephritis, Agranulocytosis, Hypophosphatemia, Bone Marrow Transplant, and Deep Brain Stimulation.

Experienced in Hypophosphatemia
Dr. Kamal N. Ummed
Hematology Oncology | Hematology | Oncology
Experienced in Hypophosphatemia
Dr. Kamal N. Ummed
Hematology Oncology | Hematology | Oncology

Nsh Cancer Institute Professional Services G LLC

1045 Southcrest Dr, Suite 200, 
Stockbridge, GA 
 (15.7 miles away)
678-289-0549
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Kamal Ummed is a Hematologist Oncology specialist and a Hematologist in Stockbridge, Georgia. Dr. Ummed is rated as a Distinguished provider by MediFind in the treatment of Hypophosphatemia. His top areas of expertise are Bone Tumor, Liposarcoma, Rhabdomyosarcoma Embryonal, and Undifferentiated Pleomorphic Sarcoma. Dr. Ummed is currently accepting new patients.

William G. Blum
Experienced in Hypophosphatemia
Dr. William G. Blum
Hematology Oncology
Experienced in Hypophosphatemia
Dr. William G. Blum
Hematology Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (4.3 miles away)
404-778-1900
Experience:
29+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

William Blum is a Hematologist Oncology provider in Atlanta, Georgia. Dr. Blum has been practicing medicine for over 29 years and is rated as an Elite provider by MediFind in the treatment of Hypophosphatemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration.

VIEW MORE HYPOPHOSPHATEMIA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hofmeister's expertise for a condition
ConditionClose
  • Elite
  • Bone Marrow Transplant
    Dr. Hofmeister is
    Elite
    . Learn about Bone Marrow Transplant.
    See more Bone Marrow Transplant experts
  • Multiple Myeloma
    Dr. Hofmeister is
    Elite
    . Learn about Multiple Myeloma.
    See more Multiple Myeloma experts
  • Smoldering Multiple Myeloma
    Dr. Hofmeister is
    Elite
    . Learn about Smoldering Multiple Myeloma.
    See more Smoldering Multiple Myeloma experts
  • Distinguished
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
    Dr. Hofmeister is
    Distinguished
    . Learn about Monoclonal Gammopathy of Undetermined Significance (MGUS).
    See more Monoclonal Gammopathy of Undetermined Significance (MGUS) experts
  • Relapsed Refractory Multiple Myeloma (RRMM)
    Dr. Hofmeister is
    Distinguished
    . Learn about Relapsed Refractory Multiple Myeloma (RRMM).
    See more Relapsed Refractory Multiple Myeloma (RRMM) experts
  • Advanced
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Hofmeister is
    Advanced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Hofmeister is
    Advanced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Graft Versus Host Disease (GvHD)
    Dr. Hofmeister is
    Advanced
    . Learn about Graft Versus Host Disease (GvHD).
    See more Graft Versus Host Disease (GvHD) experts
  • Plasmacytoma
    Dr. Hofmeister is
    Advanced
    . Learn about Plasmacytoma.
    See more Plasmacytoma experts
  • Primary Amyloidosis
    Dr. Hofmeister is
    Advanced
    . Learn about Primary Amyloidosis.
    See more Primary Amyloidosis experts
  • Schnitzler Syndrome
    Dr. Hofmeister is
    Advanced
    . Learn about Schnitzler Syndrome.
    See more Schnitzler Syndrome experts
View All 7 Advanced Conditions
  • Experienced
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Hofmeister is
    Experienced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Hofmeister is
    Experienced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Agranulocytosis
    Dr. Hofmeister is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Anemia
    Dr. Hofmeister is
    Experienced
    . Learn about Anemia.
    See more Anemia experts
  • B-Cell Lymphoma
    Dr. Hofmeister is
    Experienced
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Bone Marrow Aspiration
    Dr. Hofmeister is
    Experienced
    . Learn about Bone Marrow Aspiration.
    See more Bone Marrow Aspiration experts
View All 37 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.